<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34979838</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coumarins effectively inhibit bacterial α-carbonic anhydrases.</ArticleTitle>
        <Pagination>
          <StartPage>333</StartPage>
          <EndPage>338</EndPage>
          <MedlinePgn>333-338</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.2012174</ELocationID>
        <Abstract>
          <AbstractText>Coumarins are known to act as prodrug inhibitors of mammalian α-carbonic anhydrases (CAs, EC 4.2.1.1) but they were not yet investigated for the inhibition of bacterial α-CAs. Here we demonstrate that such enzymes from the bacterial pathogens <i>Neisseria gonorrhoeae</i> (NgCAα) and <i>Vibrio cholerae</i> (VchCAα) are inhibited by a panel of simple coumarins incorporating hydroxyl, amino, ketone or carboxylic acid ester moieties in various positions of the ring system. The nature and the position of the substituents in the coumarin ring were the factors which strongly influenced inhibitory efficacy. NgCAα was inhibited with K<sub>I</sub>s in the range of 28.6-469.5 µM, whereas VchCAα with K<sub>I</sub>s in the range of 39.8-438.7 µM. The two human (h)CA isoforms included for comparison reason in the study, hCA I and II, were less prone to inhibition by these compounds, with K<sub>I</sub>s of 137-948.9 µM for hCA I and of 296.5-961.2 µM for hCA II, respectively. These findings are relevant for discovering coumarin bacterial CA inhibitors with selectivity for the bacterial over human isoform, with potential applications as novel antibacterial agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Giovannuzzi</LastName>
            <ForeName>Simone</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical and Nutraceutical Section, Neurofarba Department, University of Florence, Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hewitt</LastName>
            <ForeName>Chad S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nocentini</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3342-702X</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical and Nutraceutical Section, Neurofarba Department, University of Florence, Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capasso</LastName>
            <ForeName>Clemente</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-3314-2411</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Agriculture and Food Sciences, CNR, Institute of Biosciences and Bioresources, Napoli, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flaherty</LastName>
            <ForeName>Daniel P</ForeName>
            <Initials>DP</Initials>
            <Identifier Source="ORCID">0000-0002-8305-0606</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Purdue Institute for Drug Discovery, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Purdue Institute of Inflammation, Immunology and Infectious Disease, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Supuran</LastName>
            <ForeName>Claudiu T</ForeName>
            <Initials>CT</Initials>
            <Identifier Source="ORCID">0000-0003-4262-0323</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical and Nutraceutical Section, Neurofarba Department, University of Florence, Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI148523</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003374">Coumarins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002256" MajorTopicYN="N">Carbonic Anhydrases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009344" MajorTopicYN="N">Neisseria gonorrhoeae</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014734" MajorTopicYN="N">Vibrio cholerae</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Carbonic anhydrase</Keyword>
        <Keyword MajorTopicYN="N">Neisseria gonorrhoeae</Keyword>
        <Keyword MajorTopicYN="N">antibacterials</Keyword>
        <Keyword MajorTopicYN="N">coumarins</Keyword>
        <Keyword MajorTopicYN="N">inhibitor</Keyword>
      </KeywordList>
      <CoiStatement>CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34979838</ArticleId>
        <ArticleId IdType="pmc">PMC8741243</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.2012174</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>(a) Smith KS, Jakubzick C, Whittam TS, Ferry JG.. 
Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc Natl Acad Sci U S A
1999;96:15184–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24794</ArticleId>
            <ArticleId IdType="pubmed">10611359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Abuaita BH, Withey JH.. 
Bicarbonate induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun
2009;77:4111–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24794</ArticleId>
            <ArticleId IdType="pubmed">10611359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Merlin C, Masters M, McAteer S, Coulson A.. 
Why is carbonic anhydrase essential to Escherichia coli?
J Bacteriol
2003;185:6415–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24794</ArticleId>
            <ArticleId IdType="pubmed">10611359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Del Prete S, Nocentini A, Supuran CT, Capasso C.. 
Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem
2020;35:1060–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24794</ArticleId>
            <ArticleId IdType="pubmed">10611359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Supuran CT.
Bacterial carbonic anhydrases as drug targets: toward novel antibiotics?
Front Pharmacol
2011;2:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132667</ArticleId>
            <ArticleId IdType="pubmed">21779249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Flaherty DP, Seleem MN, Supuran CT.. 
Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem
2021;13:1619–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132667</ArticleId>
            <ArticleId IdType="pubmed">21779249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Petreni A, De Luca V, Scaloni A, et al. . 
Anion inhibition studies of the Zn(II)-bound ι-carbonic anhydrase from the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem
2021;36:372–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132667</ArticleId>
            <ArticleId IdType="pubmed">21779249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Supuran CT, Capasso C.. 
An Overview of the Bacterial Carbonic Anhydrases. Metabolites
2017;7:56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132667</ArticleId>
            <ArticleId IdType="pubmed">21779249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Supuran CT, Capasso C.. 
Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat
2018;28:745–54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29973089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Supuran CT, Capasso C.. 
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat
2020;30:963–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29973089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Campestre CD, Luca V, Carradori S, et al. . 
Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol
2021;12:629163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29973089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Capasso C, Supuran CT.. 
An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?
J Enzyme Inhib Med Chem
2015;30:325–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29973089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Kaur J, Cao X, Abutaleb NS, et al. . 
Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem
2020;63:9540–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317130</ArticleId>
            <ArticleId IdType="pubmed">32787141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN.. 
In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother
2021;65:e01715–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317130</ArticleId>
            <ArticleId IdType="pubmed">32787141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN.. 
In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ
2021;9:e11059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317130</ArticleId>
            <ArticleId IdType="pubmed">32787141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. . 
Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis
2021;7:1969–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317129</ArticleId>
            <ArticleId IdType="pubmed">33765392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Nocentini A, Hewitt CS, Mastrolorenzo MD, et al. . 
Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem
2021;36:1061–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317129</ArticleId>
            <ArticleId IdType="pubmed">33765392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Del Prete S, Isik S, Vullo D, et al. . 
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem
2012;55:10742–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23181552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Del Prete S, De Luca V, Scozzafava A, et al. . 
Biochemical properties of a new α-carbonic anhydrase from the human pathogenic bacterium, Vibrio cholerae. J Enzyme Inhib Med Chem
2014;29:23–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23181552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> (c) Angeli A, Del Prete S, Osman SM, et al. . 
Activation studies of the α- and β-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with amines and amino acids. J Enzyme Inhib Med Chem
2018;33:227–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23181552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Ferraroni M, Del Prete S, Vullo D, et al. . 
Crystal structure and kinetic studies of a tetrameric type II β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Acta Crystallogr D Biol Crystallogr
2015;71:2449–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23181552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Urbanski LJ, Bua S, Angeli A, et al. . 
Sulphonamide inhibition profile of Staphylococcus aureus β-carbonic anhydrase. J Enzyme Inhib Med Chem
2020;35:1834–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534311</ArticleId>
            <ArticleId IdType="pubmed">32972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Fan SH, Ebner P, Reichert S, et al. . 
MpsAB is important for Staphylococcus aureus virulence and growth at atmospheric CO2 levels. Nat Commun
2019;10:3627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534311</ArticleId>
            <ArticleId IdType="pubmed">32972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Supuran CT.
Novel carbonic anhydrase inhibitors. Future Med Chem
2021;13:1935–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534311</ArticleId>
            <ArticleId IdType="pubmed">32972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Supuran CT.
Emerging role of carbonic anhydrase inhibitors. Clin Sci
2021;135:1233–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534311</ArticleId>
            <ArticleId IdType="pubmed">32972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Matsumoto Y, Miyake K, Ozawa K, et al. . 
Bicarbonate and unsaturated fatty acids enhance capsular polysaccharide synthesis gene expression in oral streptococci, Streptococcus anginosus. J Biosci Bioeng
2019;128:511–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Capasso C, Supuran CT.. 
An overview of the carbonic anhydrases from two pathogens of the oral cavity: Streptococcus mutans and Porphyromonas gingivalis. Curr Top Med Chem
2016;16:2359–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Dedeoglu N, De Luca V, Isik S, et al. . 
Cloning, characterization and anion inhibition study of a β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans. Bioorg Med Chem
2015;23:2995–3001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Burghout P, Vullo D, Scozzafava A, et al. . 
Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?
Bioorg Med Chem
2011;19:243–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Del Prete S, De Luca V, Capasso C, et al. . 
Recombinant thermoactive phosphoenolpyruvate carboxylase (PEPC) from Thermosynechococcus elongatus and its coupling with mesophilic/thermophilic bacterial carbonic anhydrases (CAs) for the conversion of CO2 to oxaloacetate. Bioorg Med Chem
2016;24:220–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26712095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) De Luca V, Del Prete S, Vullo D, et al. . 
Expression and characterization of a recombinant psychrophilic γ-carbonic anhydrase (NcoCA) identified in the genome of the Antarctic cyanobacteria belonging to the genus Nostoc. J Enzyme Inhib Med Chem
2016;31:810–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26712095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Vullo D, De Luca V, Del Prete S, et al. . 
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. Bioorg Med Chem
2015;23:1728–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26712095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) De Luca V, Vullo D, Del Prete S, et al. . 
Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. Bioorg Med Chem
2015;23:4405–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26712095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Rahman MM, Tikhomirova A, Modak JK, et al. . 
Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathog
2020;12:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7158114</ArticleId>
            <ArticleId IdType="pubmed">32318117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Modak JK, Tikhomirova A, Gorrell RJ, et al. . 
Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem
2019;34:1660–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7158114</ArticleId>
            <ArticleId IdType="pubmed">32318117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> (c) Modak JK, Liu YC, Supuran CT, Roujeinikova A.. 
Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem
2016;59:11098–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7158114</ArticleId>
            <ArticleId IdType="pubmed">32318117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Supuran CT.
Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov
2020;15:671–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32208982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Supuran CT.
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov
2008;7:168–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32208982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Mishra CB, Tiwari M, Supuran CT.. 
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today?
Med Res Rev
2020;40:2485–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32208982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) De Simone G, Supuran CT.. 
(In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem
2012;111:117–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22192857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Ozensoy Guler O, Capasso C, Supuran CT.. 
A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem
2016;31:689–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22192857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Nocentini A, Angeli A, Carta F, et al. . 
Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem
2021;36:561–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22192857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> (d) Supuran CT.
Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem
2012;27:759–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22192857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(e) Supuran CT.
How many carbonic anhydrase inhibition mechanisms exist?
J Enzyme Inhib Med Chem
2016;31:345–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22192857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Maresca A, Temperini C, Vu H, et al. . 
Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc
2009;131:3057–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19206230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Maresca A, Temperini C, Pochet L, et al. . 
Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem
2010;53:335–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19206230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Supuran CT.
Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem
2020;35:1462–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470141</ArticleId>
            <ArticleId IdType="pubmed">32779543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II . Bioorg Med Chem Lett
2010;20:4511–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470141</ArticleId>
            <ArticleId IdType="pubmed">32779543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Maresca A, Scozzafava A, Supuran CT.. 
7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett
2010;20:7255–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470141</ArticleId>
            <ArticleId IdType="pubmed">32779543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Sharma A, Tiwari M, Supuran CT.. 
Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem
2014;29:292–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470141</ArticleId>
            <ArticleId IdType="pubmed">32779543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(e) Touisni N, Maresca A, McDonald PC, et al. . 
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem
2011;54:8271–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470141</ArticleId>
            <ArticleId IdType="pubmed">32779543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Petreni A, Osman SM, Alasmary FA, et al. . 
Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases. Eur J Med Chem
2021;226:113875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34634741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Supuran CT.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem
2021;36:1702–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34634741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Fois B, Distinto S, Meleddu R, et al. . 
Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic anhydrases IX and XII: isolation, biological studies and in silico evaluation. J Enzyme Inhib Med Chem
2020;35:539–‐48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34634741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(d) Melis C, Distinto S, Bianco G, et al. . 
Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors. ACS Med Chem Lett
2018;9:725–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34634741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(e) Meleddu R, Deplano S, Maccioni E, et al. . 
Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives. J Enzyme Inhib Med Chem
2021;36:685–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34634741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Innocenti A, Supuran CT.. 
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases. Bioorg Med Chem Lett
2010;20:6208–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20833546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Innocenti A, Scozzafava A, Parkkila S, et al. . 
Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates. Bioorg Med Chem Lett
2008;18:2267–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20833546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Lopez M, Vu H, Wang CK, et al. . 
Promiscuity of carbonic anhydrase II. Unexpected ester hydrolysis of carbohydrate-based sulfamate inhibitors. J Am Chem Soc
2011;133:18452–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20833546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Kaul T, Reddy PS, Mahanty S, et al. . Biochemical and molecular characterization of stress-induced β-carbonic anhydrase from a C(4) plant, Pennisetum glaucum. J Plant Physiol
2011;168:601–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20884079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> (b) Lee RB, Smith JA, Rickaby RE.. 
Cloning, expression and characterization of the δ-carbonic anhydrase of Thalassiosira weissflogii (Bacillariophyceae). J Phycol
2013;49:170–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20884079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete S, Vullo D, De Luca V, et al. . 
Biochemical characterization of the δ-carbonic anhydrase from the marine diatom Thalassiosira weissflogii, TweCA. J Enzyme Inhib Med Chem
2014;29:906–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24456295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalifah RG.
The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem
1971;246:2561–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4994926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Supuran CT, Alterio V, Di Fiore A, et al. . 
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev
2018;38:1799–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29635752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Neri D, Supuran CT.. 
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov
2011;10:767–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29635752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(c) Thacker PS, Tiwari PL, Angeli A, et al. . 
Synthesis and biological evaluation of coumarin-linked 4-anilinomethyl-1,2,3-triazoles as potent inhibitors of carbonic anhydrases IX and XIII involved in tumorigenesis. Metabolites
2021;11:225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29635752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(a) Peperidou A, Bua S, Bozdag M, et al. . 
Novel 6- and 7-substituted coumarins with inhibitory action against lipoxygenase and tumor-associated carbonic anhydrase IX. Molecules
2018;23:153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6017447</ArticleId>
            <ArticleId IdType="pubmed">29329232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>(b) Kartsev V, Geronikaki A, Bua S, et al. . 
Extending the inhibition profiles of coumarin-based compounds against human carbonic anhydrases: synthesis, biological, and in silico evaluation. Molecules
2019;24:3580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6017447</ArticleId>
            <ArticleId IdType="pubmed">29329232</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
